S32504, a novel naphtoxazine agonist at dopamine D3/D 2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 3, 2004, Pages 921-935

  Millan, Mark J ^a   Di Cara, Benjamin ^a   Hill, Michael ^b   Jackson, Michael ^c   Joyce, Jeffrey N ^d   Brotchie, Jonathan ^b,e   McGuire, Steve ^b   Crossman, Alan ^b   Smith, Lance ^c   Jenner, Peter ^c   Gobert, Alain ^a   Peglion, Jean Louis ^a   Brocco, Mauricette ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b Williams House   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d SUN HEALTH RESEARCH INSTITUTE   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4,4A,5,6,10B HEXAHYDRO 9 CARBAMOYL 4 PROPYL 2H NAPHTH[1,2 B] 1,4 OXAZINE; ACETYLCHOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LEVODOPA; MONOAMINE; OXAZINE DERIVATIVE; OXIDOPAMINE; RACLOPRIDE; RESERPINE; ROPINIROLE; S 32504; S 32601; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; MOTOR PERFORMANCE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; STEREOSPECIFICITY; SUBSTANTIA NIGRA;

ACETYLCHOLINE; ANIMALS; CALLITHRIX; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; DYSKINESIAS; ELECTROPHYSIOLOGY; EXTRACELLULAR SPACE; HUMANS; HYPOKINESIA; INDOLES; LEVODOPA; MALE; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; OXAZINES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RESERPINE; ROTATION;

EID: 2442698940     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.062414     Document Type: Article

References (52)

1. 2 receptors on cholinergic interneurons of the dorsal striatum and nucleus accumbens of the rat. Brain Res 986:22-29.
2. Araki T, Tanji H, Fujihara K, Kato H, Imai Y, Mizugaki M, and Itoyama Y (2000) Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats. J Neural Transm 107:873-884.
3. Bennett JP, Carvey PM, Hinds TR, Johnson RD, Le WD, Phillips W, Sethy VH, Vincenzi FF, and Youdim MB (2001) Mechanisms of action of pramipexole: putative neuroprotective effects. Rev Contemp Pharmacother 12:33-57.
4. Bézard E, Brotchie JM, and Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577-587.
5. 3 receptor function. Nat Med 9:762-767.
6. 3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J Pharmacol Exp Ther 283:794-799.
7. Blum D, Torch S, Lambeng N, Nissou MF, Benabid AL, Sadoul R, and Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172.
8. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, and Stocchi F (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-DOPA. J Neural Transm 109:489-502.
9. 3 dopamine receptor agonists. Parkinsonism Relat Disord 7:213-223.
10. 4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127:1696-1702.
11. 2 dopamine receptor subtypes. J Pharmacol Exp Ther 277:775-783.
12. Di Chiara G, Morelli M, and Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17:228-233.
13. 2 agonist. Pharmacol Biochem Behav 38:147-154.
14. Fox SH, Henry B, Hill MP, Crossman AR, and Brotchie JM (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 17:1180-1187.
15. Gerlach M and Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of disease in man. J Neural Transm 103:987-1041.
16. 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther 305:338-346.
17. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, and Meltzer HY (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26:325-339.
18. 2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838:51-59.
19. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53:S26-S38.
20. Joyce JN (1993) Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine: III. Results in Parkinson's disease cases. Brain Res 600:156-160.
21. 3 receptor as a therapeutic target for antipsychotic and antiparkinson drugs. Pharmacol Ther 90:231-259.
22. Joyce JN, Borwege S, and Millan MJ (2003a) Antioxidant effects of dopamine (DA) agonists mediate neuroprotection against DA in terminally differentiated SH-SY5Y cells (Abstract). Am Soc Neurosci 29:733.10.
23. +) and in vivo against 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp Neurol 184:393-407.
24. Karasawa H, Taketo MM, and Matsui M (2003) Loss of anti-cataleptic effect of scopolamine in mice lacking muscarinic acetylcholine receptor subtype 4. Eur J Pharmacol 468:15-19.
25. 2 receptors in the shell of the nucleus accumbens: turning behaviour. Eur J Pharmacol 308:235-241.
26. Le WD, Jankovic J, Xie W, and Appel SH (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 107:1165-1173.
27. Maratos EC, Jackson MJ, Pearce RK, and Jenner P (2001) Antiparkinson activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 16:631-641.
28. Marti M, Paganini F, Stocchi S, Mela F, Beani L, Bianchi C, and Morari M (2003) Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. J Neurochem 84:792-802.
29. 2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison to ropinirole. J Pharmacol Exp Ther 309:936-950.
30. 2 receptors: I. Cellular, electrophysiological and neurochemical profile in comparison to ropinirole. J Pharmacol Exp Ther 309:903-920.
31. 3-receptors: II. Functional and behavioural profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1063-1073.
32. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, and Newman-Tancredi A (2002) Differential actions of antiparkinsonian agents at multiple classes of monoaminergic receptor: I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804.
33. 4 receptors: an in vitro and in vivo comparison to L745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo [2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 287:167-186.
34. 2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology, in press.
35. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10:2565-2573.
36. 2 receptor presents apoptosis in dopaminergic cell lines. Biochem J 73:25-32.
37. 2-adrenoceptor. J Pharmacol Exp Ther 303:805-814.
38. 2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. Brain Res 920:41-54.
39. Pearce RK, Banerji T, Jenner P, and Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset. Mov Disord 13:234-241.
40. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98:263-273.
41. 3 receptor dependent and independent mechanisms. Eur J Pharmacol 475:29-35.
42. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, and Montastruc JL (2003) Limitations of current Parkinson's disease therapy. Ann Neurol 53:S3-S15.
43. Raz A, Feingold A, Zelanskaya V, Vaadia E, and Bergman H (1996) Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates. J Neurophysiol 76:2083-2088.
44. Sato K, Ueda H, Okumura F, and Misu Y (1994) Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson's model rats. Neurosci Lett 173:59-62.
45. Schapira AH and Olanow CW (2003) Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 53:S149-S159.
46. 3 receptor blockade and not stimulation, is associated with anti-parkinsonian activity in the MPTP-lesioned, non-human primate model of Parkinson's disease. Neurology 58:493-494.
47. Skalisz LL, Beijamini V, Joca SL, Vital MA, Da Cunha C, and Andreatini R (2002) Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson's disease association. Prog Neuropsychopharmacol Biol Psychiatry 26:879-883.
48. Smith LA, De Salvia M, Jenner P, and Marsden CD (1996) An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov Disord 11:125-135.
49. 3 receptor mRNA in a rodent model of behavioural sensitization to levo-dopa. Neuroscience 116:307-314.
50. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, et al. (2003) Slower progression of Parkinson's disease with ropinirole vs levodopa: the REAL-PET study. Ann Neurol 54:93-101.
51. 3 receptors modulate evoked dopamine release from slices of rat nucleus accumbens via muscarinic receptors, but not from the striatum. J Pharmacol Exp Ther 291:994-998.
52. Zarrindast MR and Minaian A (1991) Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice. Gen Pharmacol 22:1017-1021.